These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 35900152)

  • 21. Sirt1 regulates canonical TGF-β signalling to control fibroblast activation and tissue fibrosis.
    Zerr P; Palumbo-Zerr K; Huang J; Tomcik M; Sumova B; Distler O; Schett G; Distler JH
    Ann Rheum Dis; 2016 Jan; 75(1):226-33. PubMed ID: 25180292
    [TBL] [Abstract][Full Text] [Related]  

  • 22. p300 is elevated in systemic sclerosis and its expression is positively regulated by TGF-β: epigenetic feed-forward amplification of fibrosis.
    Ghosh AK; Bhattacharyya S; Lafyatis R; Farina G; Yu J; Thimmapaya B; Wei J; Varga J
    J Invest Dermatol; 2013 May; 133(5):1302-10. PubMed ID: 23303459
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanisms of skin fibrosis in systemic sclerosis.
    Jinnin M
    J Dermatol; 2010 Jan; 37(1):11-25. PubMed ID: 20175837
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antifibrotic effects and mechanisms of mesenchymal stem cell-derived exosomes in a systemic sclerosis mouse model: Possible contribution of miR-196b-5p.
    Baral H; Uchiyama A; Yokoyama Y; Sekiguchi A; Yamazaki S; Amalia SN; Inoue Y; Ogino S; Torii R; Hosoi M; Matsuzaki T; Motegi SI
    J Dermatol Sci; 2021 Oct; 104(1):39-47. PubMed ID: 34479773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elevated Fibronectin Levels in Profibrotic CD14
    Rudnik M; Hukara A; Kocherova I; Jordan S; Schniering J; Milleret V; Ehrbar M; Klingel K; Feghali-Bostwick C; Distler O; Błyszczuk P; Kania G
    Front Immunol; 2021; 12():642891. PubMed ID: 34504485
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A possible contribution of altered cathepsin B expression to the development of skin sclerosis and vasculopathy in systemic sclerosis.
    Noda S; Asano Y; Akamata K; Aozasa N; Taniguchi T; Takahashi T; Ichimura Y; Toyama T; Sumida H; Yanaba K; Tada Y; Sugaya M; Kadono T; Sato S
    PLoS One; 2012; 7(2):e32272. PubMed ID: 22384200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Basic fibroblast growth factor inhibits basal and transforming growth factor-beta induced collagen alpha 2(I) gene expression in scleroderma and normal fibroblasts.
    Ichiki Y; Smith EA; LeRoy EC; Trojanowska M
    J Rheumatol; 1997 Jan; 24(1):90-5. PubMed ID: 9002017
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased expression of the transforming growth factor β-inducible gene HIC-5 in systemic sclerosis skin and fibroblasts: a novel antifibrotic therapeutic target.
    Piera-Velazquez S; Fertala J; Huaman-Vargas G; Louneva N; Jiménez SA
    Rheumatology (Oxford); 2020 Oct; 59(10):3092-3098. PubMed ID: 32442272
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suppressive Regulation by MFG-E8 of Latent Transforming Growth Factor β-Induced Fibrosis via Binding to αv Integrin: Significance in the Pathogenesis of Fibrosis in Systemic Sclerosis.
    Fujiwara C; Uehara A; Sekiguchi A; Uchiyama A; Yamazaki S; Ogino S; Yokoyama Y; Torii R; Hosoi M; Suto C; Tsunekawa K; Murakami M; Ishikawa O; Motegi SI
    Arthritis Rheumatol; 2019 Feb; 71(2):302-314. PubMed ID: 30175895
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The transcription factor GLI2 as a downstream mediator of transforming growth factor-β-induced fibroblast activation in SSc.
    Liang R; Šumová B; Cordazzo C; Mallano T; Zhang Y; Wohlfahrt T; Dees C; Ramming A; Krasowska D; Michalska-Jakubus M; Distler O; Schett G; Šenolt L; Distler JH
    Ann Rheum Dis; 2017 Apr; 76(4):756-764. PubMed ID: 27793816
    [TBL] [Abstract][Full Text] [Related]  

  • 31. S100A4 amplifies TGF-β-induced fibroblast activation in systemic sclerosis.
    Tomcik M; Palumbo-Zerr K; Zerr P; Avouac J; Dees C; Sumova B; Distler A; Beyer C; Cerezo LA; Becvar R; Distler O; Grigorian M; Schett G; Senolt L; Distler JH
    Ann Rheum Dis; 2015 Sep; 74(9):1748-55. PubMed ID: 24709861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The membrane-associated adaptor protein DOK5 is upregulated in systemic sclerosis and associated with IGFBP-5-induced fibrosis.
    Yasuoka H; Yamaguchi Y; Feghali-Bostwick CA
    PLoS One; 2014; 9(2):e87754. PubMed ID: 24551065
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Th17 cells and IL-17 promote the skin and lung inflammation and fibrosis process in a bleomycin-induced murine model of systemic sclerosis.
    Lei L; Zhao C; Qin F; He ZY; Wang X; Zhong XN
    Clin Exp Rheumatol; 2016; 34 Suppl 100(5):14-22. PubMed ID: 26750756
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The involvement of leucine-rich α-2 glycoprotein in the progression of skin and lung fibrosis in bleomycin-induced systemic sclerosis model.
    Nakajima H; Nakajima K; Serada S; Fujimoto M; Naka T; Sano S
    Mod Rheumatol; 2021 Nov; 31(6):1120-1128. PubMed ID: 33535851
    [TBL] [Abstract][Full Text] [Related]  

  • 35. X-linked inhibitor of apoptosis protein (XIAP) inhibition in systemic sclerosis (SSc).
    Bergmann C; Hallenberger L; Chenguiti Fakhouri S; Merlevede B; Brandt A; Dees C; Zhu H; Zehender A; Zhou X; Schwab A; Chen CW; Györfi AH; Matei AE; Chakraborty D; Trinh-Minh T; Rauber S; Coras R; Bozec A; Kreuter A; Ziemer M; Schett G; Distler JHW
    Ann Rheum Dis; 2021 Aug; 80(8):1048-1056. PubMed ID: 33903093
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interferon regulatory factor 7 (IRF7) represents a link between inflammation and fibrosis in the pathogenesis of systemic sclerosis.
    Wu M; Skaug B; Bi X; Mills T; Salazar G; Zhou X; Reveille J; Agarwal SK; Blackburn MR; Mayes MD; Assassi S
    Ann Rheum Dis; 2019 Nov; 78(11):1583-1591. PubMed ID: 31439591
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ciprofloxacin has antifibrotic effects in scleroderma fibroblasts via downregulation of Dnmt1 and upregulation of Fli1.
    Bujor AM; Haines P; Padilla C; Christmann RB; Junie M; Sampaio-Barros PD; Lafyatis R; Trojanowska M
    Int J Mol Med; 2012 Dec; 30(6):1473-80. PubMed ID: 23041765
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis.
    Soare A; Györfi HA; Matei AE; Dees C; Rauber S; Wohlfahrt T; Chen CW; Ludolph I; Horch RE; Bäuerle T; von Hörsten S; Mihai C; Distler O; Ramming A; Schett G; Distler JHW
    Arthritis Rheumatol; 2020 Jan; 72(1):137-149. PubMed ID: 31350829
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Autocrine TGF-beta signaling in the pathogenesis of systemic sclerosis.
    Ihn H
    J Dermatol Sci; 2008 Feb; 49(2):103-13. PubMed ID: 17628443
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dersimelagon, a novel oral melanocortin 1 receptor agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis.
    Kondo M; Suzuki T; Kawano Y; Kojima S; Miyashiro M; Matsumoto A; Kania G; Błyszczuk P; Ross RL; Mulipa P; Del Galdo F; Zhang Y; Distler JHW
    Arthritis Res Ther; 2022 Sep; 24(1):210. PubMed ID: 36050717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.